DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Precose (Acarbose) - Summary



PRECOSE® (acarbose tablets) is an oral alpha-glucosidase inhibitor for use in the management of type 2 diabetes mellitus.

PRECOSE is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

See all Precose indications & dosage >>


Media Articles Related to Precose (Acarbose)

Acarbose Offers No CVD Protection in ACE, but May Cut Diabetes Risk
Source: Medscape Diabetes & Endocrinology Headlines [2017.09.14]
A study of acarbose was conducted in a Chinese population with impaired glucose tolerance and established cardiovascular disease.
Medscape Medical News

Postprandial Glucose Drug No Help for Established Heart Disease (CME/CE)
Source: MedPage Today Endocrinology [2017.09.13]
(MedPage Today) -- Acarbose delayed diabetes onset but didn't prevent CV events

more news >>

Published Studies Related to Precose (Acarbose)

Effects of acarbose treatment on markers of insulin sensitivity and systemic inflammation. [2011.06]
BACKGROUND: This study assessed the effect of postprandial glucose reduction by acarbose on insulin sensitivity and biomarkers of systemic inflammation... CONCLUSIONS: Reduction of the glycemic load by acarbose decreased fasting levels of proinsulin but had no effect on adiponectin and whole-body insulin sensitivity as well as biomarkers reflecting inflammation. The preventive effects of acarbose on type 2 diabetes mellitus and cardiovascular risk need further investigation and cannot be explained by changes of insulin resistance and inflammatory biomarkers.

Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. [2011.01.25]
The aim of this study was to evaluate the effects of acarbose on inflammatory biomarkers and insulin resistance in diabetic patients before and after a standardized oral fat load (OFL). Ninety six patients were assigned to take acarbose 50mg three times a day and 92 to take placebo; after the first month acarbose was titrated to 100mg three times a day...

A prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes. [2010.11]
OBJECTIVE: The present study was a prospective, parallel group, open-labeled, comparative, multicentric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetic patients... CONCLUSIONS: Fixed dose combination of acarbose and metformin was well tolerated and it was superior to metformin monotherapy in controlling FBG, PPBG and HbA(1C) levels in Type 2 Diabetes Mellitus patients.

Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: A one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease. [2010.08]
OBJECTIVE: This study examined the effect of acarbose therapy on carotid intima-media thickness (IMT) in patients with established coronary artery disease (CAD) who had been newly diagnosed with impaired glucose tolerance (IGT) or mild type 2 diabetes mellitus (T2DM)... CONCLUSION: In this small, open-label study in patients with established CAD who were newly diagnosed with IGT or mild T2DM, 12 months of treatment with acarbose was associated with a beneficial effect in terms of preventing the progression of carotid IMT compared with control, although it was not associated with a significant decrease in IMT from baseline. UMIN (University Hospital Medical Information Network) Clinical Trials Registry identifier: UMIN000000544. Copyright (c) 2010 Excerpta Medica Inc. All rights reserved.

Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. [2010.03.24]
BACKGROUND: Postprandial hyperglycemia is believed to affect vascular endothelial function. The aim of our study was to compare the effects of acarbose and nateglinide on postprandial endothelial dysfunction... CONCLUSIONS: Our results suggest that acarbose improves postprandial endothelial function by improvement of postprandial hyperglycemia, independent of postprandial hyperinsulinemia. Acarbose may thus have more beneficial effects on postprandial endothelial function in patients with type 2 diabetes than nateglinide.

more studies >>

Clinical Trials Related to Precose (Acarbose)

Acarbose and Older Adults With Postprandial Hypotension [Recruiting]
The current proposal will determine if blocking carbohydrate intake in the small intestine with Acarbose can be a possible therapy for older adults with (PPH) Post Prandial Hypotension (a drop of blood pressure after eating), which can result in falls.

24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy [Active, not recruiting]

SMART Study - A 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active

Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared with Acarbose when in Combination with Metformin in Patients with Type 2 Diabetes Mellitus (T2D) Inadequately Controlled with Metformin Monotherapy

Bioequivalence Study for Acarbose / Metformin FDC [Completed]
To establish the bioequivalence between Acarbose / Metformin FDC (50mg / 500mg) and loose combination of Acarbose (Glucobay) (50mg) and Metformin (Glucophage) (500mg).

Acarbose, Postprandial Hypotension and Type 2 Diabetes [Completed]
Postprandial hypotension carries a risk of significant morbidity and morbidity including syncope, falls, dizziness, fatigue, stroke and myocardial infarction. Current therapy consists of dietary manipulation (smaller meals) caffeine and octreotide injections all of which are suboptimal and poorly studied. The study hypothesis is that administration of Acarbose will decrease the drop in blood pressure and increase in heart rate in response to food in people with Type 2 diabetes. Acarbose suppresses postprandial glycemia be slowing digestion in the small intestine and delaying gastric emptying.

This is a placebo-controlled cross over study involving 2 - 4 hour Meal Tests. During the

meal tests heart rate, blood pressure, cerebral artery velocity will be measured. During one meal test subjects will receive Acarbose 50 mg po and during the other will receive placebo. Order of treatment assignment will be done in randomized fashion. A total of approximately 200 cc of blood will be drawn during each meal test.

Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients [Completed]
Primary objective To evaluate the efficacy of Acarbose added on top of Metformin and Sitagliptin that were combinedly administered to subjects with type-II diabetes, along with placebos. Secondary objectives 1. To compare a Metformin-Sitagliptin combination and a Sitagliptin-Acarbose combination in efficacy 2. To evaluate the 6-month efficacy of Acarbose added on top of the Metformin-Sitagliptin combination

more trials >>

Reports of Suspected Precose (Acarbose) Side Effects

Blood Glucose Increased (2)Adverse Reaction (2)Traumatic Fracture (1)Fall (1)Loss of Consciousness (1)Malaise (1)Thinking Abnormal (1)Diabetes Mellitus Inadequate Control (1)Decreased Appetite (1)Drug Hypersensitivity (1)more >>

Page last updated: 2017-09-14

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017